Pharmacoeconomic Analysis of Axitinib as Second-Line Treatment for Metastatic Renal Cell Carcinoma
Value Health
.
2014 Nov;17(7):A638-9.
doi: 10.1016/j.jval.2014.08.2299.
Epub 2014 Oct 26.
Authors
A Kulikov
1
,
I Komarov
1
,
I Zinchuk
2
Affiliations
1
First Moscow State Medical University named after I. M. Sechenov, Moscow, Russia.
2
Moscow pharmaceutical society, Moscow, Russia.
PMID:
27202282
DOI:
10.1016/j.jval.2014.08.2299
No abstract available